These findings provide promising rationale for the use of CBD in opioid . These data suggest that combined cannabis and opioid-antagonist. Used in combination with opioid pain medications, cannabis can the promise that cannabis might hold as a standardized pain treatment. The opioid crisis is a complex problem with many components. One of Some people believe that marijuana could be one of them. . In that same hopeful spirit , we share some of the most promising solutions currently in.
Combination Cannabis: Promising & Opioids A
Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: Is cannabis use associated with less opioid use among people who inject drugs?
Cannabis as a substitute for opioid-based pain medication: Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. Effects of legal access to cannabis on scheduled II-V drug prescriptions. J Am Med Dir Assoc. Opioid and cannabinoid synergy in a mouse neuropathic pain model. Pharmacological treatment of painful HIV-associated sensory neuropathy: Synergistic affective analgesic interaction between deltatetrahydrocannabinol and morphine.
Cannabinoid-opioid interaction in chronic pain. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: Int J Drug Policy.
Cannabis as a substitute for alcohol and other drugs. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Comparison of antinociceptive action of morphine in the periaqueductal gray, medial and paramedial medulla in rat. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.
Interactions between delta 9 -tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: Cellular actions of opioids and other analgesics: Clin Exp Pharmacol Physiol.
Anatomy and physiology of a nociceptive modulatory system. Tolerance to the antinociceptive effect of morphine in the absence of short-term presynaptic desensitization in rat periaqueductal gray neurons. The Brainstem and Nociceptive Modulation. A Comprehensive Reference 5. Cambridge MA, , pp.
Postsynaptic mGluR mediated excitation of neurons in midbrain periaqueductal grey. Kampman K, Jarvis M. American Society of Addiction Medicine ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. The need for psychosocial interventions to facilitate the transition to extended-release naltrexone XR-NTX treatment for opioid dependence: Maintenance medication for opiate addiction: Center for Substance Abuse Treatment.
Medication-assisted treatment for opioid addiction in opioid treatment programs. Medication-assisted treatment of opioid use disorder: Medication-assisted treatment with methadone: A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Treatment of opioid-use disorders. Methadone and buprenorphine for the management of opioid dependence: Medical safety and side effects of methadone in tolerant individuals. Pharmacological treatments for drug misuse and dependence. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: Management of drug and alcohol withdrawal. Where is buprenorphine dispensed to treat opioid use disorders?
The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Encyclopedia of substance abuse prevention, treatment, and recovery. Thousand Oaks, CA, Sublingual buprenorphine for chronic pain: Abuse liability of intravenous buprenorphine vs. Abuse liability of buprenorphine—naloxone tablets in untreated IV drug users. Wesson DR, Ling W. The clinical opiate withdrawal scale COWS. Why is buprenorphine coformulated with naloxone?
Analysis of the abuse and diversion of the buprenorphine transdermal delivery system. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Buprenorphine treatment for narcotic addiction: Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, — Barriers to primary care physicians prescribing buprenorphine. Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: Am J Drug Alcohol Abuse.
Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat. Post market drug safety information for patients and providers. Physician requirements to prescribe buprenorphine. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: Deikel SM, Carder B. Attentuation of precipitated abstinence in methadone-dependent rats by delta9-THC.
Endocannabinoid system and opioid addiction: Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC. No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. Functional interaction between opioid and cannabinoid receptors in drug self-administration.
Cannabidiol disrupts the reconsolidation of contextual drug-associated memories in Wistar rats. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids.
Prog Neuropsychopharmacol Biol Psychiatry. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Cannabidiol is a partial agonist at dopamine D2 high receptors, predicting its antipsychotic clinical dose.
Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. A novel observational method for assessing acute responses to cannabis: Safety of oral dronabinol during opioid withdrawal in humans.
Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.
Variations in cannabis use level and correlates in opiate-users on methadone maintenance treatment: The analgesic effect of oral deltatetrahydrocannabinol THC , morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. J Pain Symptom Manag. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. Other reasons for nonresponse, besides lack of interest, include people who are no longer patients and those who chose not to participate for other reasons such as privacy concerns.
One of the major limitations of cannabis research is the difficulty in determining how much cannabis participants are using. Variations in strength of product, size of vessel, and social use patterns all impact the reliability and validity of consumption measures. This survey did not ask participants to estimate their amount of consumption and therefore cannot comment on reported effective doses.
This study did not ask participants if the opioids they consumed were from a prescription or by self-medication. The study also did not inquire as to the specific types of opioids being consumed. The results of this study provide implications from both a micro and macro level. First, from the macro level, there have been three previously published indicators of public health changes in states that permit medical cannabis: Given that the participants in this study reported a greater likelihood of using cannabis as a substitute in a less stigmatized and easily accessible environment, it makes sense why we would see these changes in locations where medical cannabis is sanctioned versus places where it is illegal.
At the micro level, there is a great deal of individual risk associated with prolonged use of opioids and perhaps even nonopioid-based pain medications. The prescribing of opioids has not been curbed in the United States, despite the growing number of fatal overdoses and reported dependence.
Providing the patient with the option of cannabis as a method of pain treatment alongside the option of opioids might assist with pain relief in a safer environment with less risk. A society with less opioid dependent people will result in fewer public health harms. Cite this article as: National Center for Biotechnology Information , U. Journal List Cannabis Cannabinoid Res v. Published online Jun 1. Find articles by Amanda Reiman.
Find articles by Mark Welty. Find articles by Perry Solomon. Author information Copyright and License information Disclaimer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC.
Associated Data Supplementary Materials Supplemental data. Materials and Methods This study utilized a cross-sectional survey to gather data about the use of cannabis as a substitute for opioid and nonopioid-based pain medication.
Sampling The survey was administered through e-mail to a database of 67, medical cannabis patients in the state of California using the HelloMD patient database. Open in a separate window. Discussion Supporting the results of previous research, this study can conclude that medical cannabis patients report successfully using cannabis along with or as a substitute for opioid-based pain medication.
Limitations This is a study of patient self-report through online survey. Response rate The survey yielded responses from participants, which is a response rate of 4. Amount of cannabis consumed One of the major limitations of cannabis research is the difficulty in determining how much cannabis participants are using. Prescription status of opioids This study did not ask participants if the opioids they consumed were from a prescription or by self-medication.
Conclusions The results of this study provide implications from both a micro and macro level. Supplementary Material Supplemental data: Click here to view.
Author Disclosure Statement No competing financial interests exist. Centers for Disease Control. Injury prevention and control: Medical cannabis laws and opioid analgesic overdose mortality in the United States, — Medical cannabis laws reduce prescription medication use in Medicare Part D. CDC guideline for prescribing opioids for chronic pain—United States, The current literature review concludes that the use of marijuana for opioid addiction is safe and effective.
Certainly, insufficient literature is available to establish the benefits and harms of medical cannabis as a therapy option for opioid addiction. The use of opioids dramatically increased during the s following relaxed regulations on the need for the drug to function in pain management.
However, as the indication of opiates gained traction, more parallel use of the drug especially for addiction raised more concerns about its benefits compared to the harm it poses [ 1 ].
The flop in the earlier realization of its peril thus leads to increased opioids related deaths. In the United States, prescription opioid-related overdoses stand as the current leading incidences of preventable deaths. On average, 91 Americans are killed every day due to opioid-related drug overdoses. Canada, a second country after the US, records an increased pattern of the use and abuse of opioids.
For instance, Canada is reported to have had about 2, incidences of opioid-related deaths in alone [ 2 ]. As such, following these incidences, it is apparent that the use of prescription opioids are associated with addiction that pits more harm on the use of the drug for pain management compared to its benefits. Besides, a growing toll related to the opioid dependence in the United States, Canada, and the world as a whole necessitates a diversity of novel harm-reduction interventions.
Evidence from research indicates that conventional pharmaceutical intervention on opioid addiction through the use of buprenorphine and methadone pose the risk of harmful drug interaction and related overdose [ 3 ]. Instead, the intervention increases problems including addiction and burden to a number of medications used, which limits longterm treatment options for these patients.
As such, the current research affirms the effectiveness of Cannabis sativa marijuana as a suitable therapeutic option for the management of opioidbased addictions and treating chronic pain.
Marijuana has for long been used as a recreational drug but not readily indicated for medicinal purposes [ 5 ].
Even though clinical trials indicate promising results on the use of the drug for pain management, it is not currently approved for acute or chronic pain. Conventional research on cannabis affirms that the drug can be effective in opioid-induced pain relief and treatment of opioid addiction.
The use of marijuana reduces cravings for heroin addicts while at the same time manages the withdrawal symptoms associated with the addiction to opiates [ 6 ]. However, despite these benefits, the use of cannabis might pose adverse effects and related risk of addiction.
It is therefore essential to conduct expanded research to assess the potential benefits and risk profile associated with the use of marijuana for treatment of opioid addiction. In order to address the objectives of this research, the study conducted a systematic literature review of published articles in the United States of America and Canada. Medical databases were searched to identify peer-reviewed journal articles published between the years and The eligible study articles were systematic reviews and addressed the use of medical cannabis for the treatment of opioid addiction [ 1 ].
The study reviews met the inclusion criteria if they were systematic reviews on the use of MC for opioid addiction treatment, peerreviewed articles, and published in English. On the other hand, journal articles were excluded if they were non-systematic reviews.
Nonetheless, the studies incorporated for the research were those based on randomized control trials RCTs. Besides, controlled non-randomized clinical trials CCTs , and prospective and retrospective comparative cohort research design were used to analyze and compare published comprehensive data on the use of cannabis as an adjunct treatment for opioid addiction. The research used information sources developed from searching medical subject headings Mesh and text words related to the use of medical cannabis for treatment of opioid addiction on selected databases.
So as to identify systematic reviews, the study used search terms combined with appropriate Boolean operators which included the subject heading terms for three key aspects: In the search, totaling to unique hits, search articles were removed leading to a screening of 30 full-text journals.
Out of these, 8 full-text papers were excluded since they used non-randomized control trials. Out of the 22 remaining articles, 7 were of low quality while 5 were of moderate quality and 10 yielded results of high quality.
The data in each of the studies were summarized as per the following aspects:
The Benefits and Effects of Using Marijuana as a Pain Agent to Treat Opioid Addiction
The interactions between opioids and cannabis have been explored at the serve as a promising treatment for opioid-related addictive behaviours. if and how THC, CBD or perhaps combinations of both, might serve to. With the widespread loosening of marijuana laws, researchers should step up show promising improvements in opioid withdrawal symptoms and and retains a safe profile when combined with a strong opioid agonist. for Medicinal Cannabis Research released a report of its findings Used in combination with opioid pain medications, . Pain: A Prospective Open-label Study.